Uncategorized Archives - Page 20 of 137

MondayJan 08, 2024 9:00 am

Sigyn Therapeutics Inc. (SIGY) Is ‘One to Watch’

Sigyn Therapeutics in May 2023 announced patent and trademark applications for its ImmunePrep commercialization platform In October 2022, the company announced patent and trademark applications for ChemoPrep and ChemoPure to enhance chemotherapy and reduce toxicity Sigyn Therapeutics in September 2022 announced plans to conduct first-in-human feasibility studies in end-stage renal disease patients In August 2022, the company commenced trading on the OTCQB Venture Market Sigyn Therapeutics (OTCQB: SIGY) is a development-stage medical technology company headquartered in San Diego, California. The company’s therapeutic candidates include Sigyn Therapy(TM) to address pathogen-associated inflammatory disorders, the ImmunePrep(TM) platform to enhance the performance of immunotherapeutic antibodies,…

TuesdayJan 02, 2024 9:00 am

Clene Inc.’s (NASDAQ: CLNN) Phase 2 REPAIR-PD and REPAIR-MD Trials Indicate CNM-Au8(R)’s Ability to Increase Key Brain Metabolites, Supporting Advancement to Phase 3 Trials

Clene Inc., a late clinical-stage biopharmaceutical company focused on developing solutions that improve mitochondrial health and protect neuronal function to treat neurodegenerative diseases, recently announced the publication of a peer-reviewed article The article describes results from two Phase 2a clinical trials, REPAIR-PD and REPAIR-MS, which evaluated the effects of CNM-Au8, the company’s lead drug candidate, on brain energy metabolite levels in participants with Parkinson’s Disease and Multiple Sclerosis, respectively Researchers measured key brain metabolites, such as NADH and NAD+, which are involved in neuronal energy production, utilization, and maintenance, for changes from baseline with daily, oral treatment of CNM-Au8 over…

TuesdayDec 19, 2023 9:00 am

Oncologist Explores Whether Including Fiber in Diets Boosts Immunotherapy Outcomes

We all know that a diet high in fiber is good for us, with studies suggesting that consuming a high-fiber diet can lower an individual’s risk for some cancers. Now, researchers are looking into whether a high-fiber diet can help patients with cancer fight a cancer diagnosis by boosting immunotherapy effectiveness. Previous research involving melanoma patients already determined that those with diets that were high in fiber responded better to immunotherapy. At the forefront of this latest research is assistant professor Brendan Guercio from the Wilmot Cancer Institute. Guercio has specialized in hematology/oncology and works as a medical oncologist who…

MondayDec 18, 2023 10:30 am

How Clene Inc. (NASDAQ: CLNN) CNM-Au8(R) Takes Advantage of Gold Nanocrystals to Target Neurodegenerative Disorders

Clene, a late clinical-stage biopharmaceutical company, creates clean-surfaced, catalytically active nanocrystals that directly modulate biological systems, including the central nervous system, by improving mitochondrial health The company’s lead investigational candidate, CNM-Au8(R), is currently in development as a disease-modifying treatment for people living with specific types of neurodegenerative disorders (“ND”), namely amyotrophic lateral sclerosis (“ALS”), Parkinson’s Disease, and multiple sclerosis (“MS”) Neurodegenerative disorders are characterized by neurodegeneration – the progressive loss of neuron structure, neuronal functions, and finally, the neurons themselves Nanotherapeutics are in development to stop or reverse neurodegeneration using novel approaches to address the mitochondrial deficits and bioenergetic crises…

MondayDec 18, 2023 9:45 am

PaxMedica Inc. (NASDAQ: PXMD) Fireside Chat with CEO Howard Weisman Sheds Light on Company Achievements for ASD Therapy Pipeline

The CDC estimates 1 out of 36 children in the United States have been diagnosed with Autism Spectrum Disorder – with a therapeutic market potential of $3.42 billion by 2030 PaxMedica’s mission is to help eliminate, reduce, or modulate the troublesome aspects of ASD, an unmet medical need in the industry CEO Howard Weisman shared important updates and achievements in the company’s pipeline, financial outlook, and future vision In a 2020 report released by the Centers for Disease Control and Prevention (“CDC”), it was estimated that 1 out of 36 children had been diagnosed with autism spectrum disorder (“ASD”) in…

FridayDec 15, 2023 9:45 am

SOHM Inc. (SHMN) Releases New Product Line and Expands Manufacturing Operations in Carlsbad, California

SOHM is launching a line of 13 new chewables that offer a range of health benefits and expand the company's preventative care product portfolio The new line will be available online through Amazon.com and the company's direct-to-consumer website and will be showcased at industry conferences in 2024 SOHM is addressing its increased product demand by establishing a new CDMO GMP manufacturing facility in Carlsbad, California The new manufacturing facility is expected to be open by the end of 2023, and shareholders will be updated about its operations during its year-end 2023 report SOHM (OTC: SHMN), a pharmaceutical, nutraceutical, and cosmeceutical…

WednesdayDec 13, 2023 9:00 am

SOHM Inc.’s (SHMN) New Gene-Editing Technology Holds Potential to Revolutionize the Field of Cardiology, With Superior Capabilities Over Other Gene-Editing Systems

SOHM recently acquired ABBIE, a world-class gene-editing platform capable of inserting larger DNA sequences, including full genes, into a desired location of the target cell’s genome ABBIE is poised to facilitate drug development, with SOHM confident that its new gene-editing technology can revolutionize the field of cardiology by supporting new ways of discovering and developing drugs The ABBIE platform system is easy to operate and boasts high efficiency, low cost, and simple design ABBIE improves on some of the shortcomings of CRISPR-Cas9 as well as other gene-editing technologies, such as enabling researchers to edit genes of a large number of…

TuesdayDec 12, 2023 9:00 am

Smart Trackers Could Detect Aging-Related Complications in Seniors

Wearable smart devices that track daily circadian rest-activity rhythms may allow for the detection of frailty-related health risks in seniors more than six years before the problems occur. A new study from Harvard-affiliated Brigham and Women’s Hospital has found that smart trackers could aid in the prediction of age-related health risks long before incidents happen. Older populations tend to face age-related declines in their psychological functions as they grow older, especially individuals who are genetically predisposed to develop certain age-related psychological conditions. In most cases, however, these conditions often become apparent once the illness has set in and symptoms have…

MondayDec 11, 2023 11:15 am

SOHM Inc. (SHMN) Taps into UACI’s Robust Resources and Specialized Infrastructure for ABBIE Advancement

SOHM, a generic drug manufacturing and distributing innovator, announced its development collaboration with the University of Arizona Center for Innovation (“UACI”) for the advancement of its ABBIE platform In the arrangement, SOHM will establish offices and a wet lab bench, taking advantage of UACI’s robust and specialized infrastructure SOHM’s management is optimistic about the collaboration and is confident that this is but the first step toward deepening new lab operations It also marks a significant milestone, as it anticipates monetizing ABBIE off-the-shelf, non-viral gene editing kits SOHM (OTC: SHMN), a generic drug manufacturing and distributing innovator, just announced its development…

MondayDec 11, 2023 9:00 am

Astrotech Corp. (NASDAQ: ASTC) Is ‘One to Watch’

In November 2023, the company announced a purchase order from a Romanian company for seven TRACER 1000 ETDs to be deployed in a European airport Astrotech announced in June 2023 that its board unanimously rejected an unsolicited acquisition proposal from BML Investment Partners In May 2023, the company announced a purchase order from a Romanian company for 17 TRACER 1000 ETDs, to be delivered during calendar 2023 Astrotech confirmed test results from field trials of the AgLAB 1000-D2 mass spectrometer for hemp and cannabis producers, improving yields by an average of 24% In December 2022, the company effected a 1-for-30…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Sigyn Therapeutics Inc. (SIGY) Is ‘One to Watch’

Clene Inc.’s (NASDAQ: CLNN) Phase 2 REPAIR-PD and REPAIR-MD Trials Indicate CNM-Au8(R)’s Ability to Increase Key Brain Metabolites, Supporting Advancement to Phase 3 Trials

Oncologist Explores Whether Including Fiber in Diets Boosts Immunotherapy Outcomes

How Clene Inc. (NASDAQ: CLNN) CNM-Au8(R) Takes Advantage of Gold Nanocrystals to Target Neurodegenerative Disorders

PaxMedica Inc. (NASDAQ: PXMD) Fireside Chat with CEO Howard Weisman Sheds Light on Company Achievements for ASD Therapy Pipeline

SOHM Inc. (SHMN) Releases New Product Line and Expands Manufacturing Operations in Carlsbad, California

SOHM Inc.’s (SHMN) New Gene-Editing Technology Holds Potential to Revolutionize the Field of Cardiology, With Superior Capabilities Over Other Gene-Editing Systems

Smart Trackers Could Detect Aging-Related Complications in Seniors

SOHM Inc. (SHMN) Taps into UACI’s Robust Resources and Specialized Infrastructure for ABBIE Advancement

Astrotech Corp. (NASDAQ: ASTC) Is ‘One to Watch’

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search